-
UPDATE: Cantor Fitzgerald Reduces PT to $37 on Endo Pharmaceuticals Holdings; Settlement Less Favorable Than Hoped
Wednesday, May 30, 2012 - 8:43amCantor Fitzgerald reiterates its Hold rating on Endo Pharmaceuticals Holdings (NASDAQ: ENDP) Cantor Fitzgerald notes, "We had modeled a 4Q:14 generic launch and have updated our numbers to reflect the most conservative scenario of a Sept. 15, 2013 Watson (NYSE: WPI, NC) generic. We have also...
Read More >> -
UPDATE: Cantor Fitzgerald Raises PT to $30 on Ventrus Biosciences on Hemorrhoid Results Confidence
Wednesday, May 30, 2012 - 8:43amCantor Fitzgerald reiterates its Buy rating on Ventrus Biosciences (NASDAQ: VTUS) and raises its price target from $29 to $30. Cantor Fitzgerald comments, "At Digestive Disease Week (DDW) we spoke with several investigators in the Phase III hemorrhoid trial who indicated that study patients were...
Read More >> -
UPDATE: Cantor Fitzgerald Initiates Coverage on Cross Country Healthcare
Tuesday, May 29, 2012 - 8:27amAccording to a research report published this morning, Cantor Fitzgerald has initiated Cross Country Healthcare (NASDAQ: CCRN) with a Buy rating and $6 PT. In the report, Cantor Fitzgerald said, "After years of economic headwinds, Cross Country's fundamentals have improved, and we believe that the...
Read More >> -
Thursday, May 24, 2012 - 1:27pm
NetApp's Robust Quarter Bugged by Guidance Glitch
In what appeared to be a positive fourth quarter earnings report by NetApp (NASDAQ: NTAP) unfortunately took a sharp turn when management's F1Q13 guidance left analysts scratching their heads. Research firms responded to the cloudy projection with a slew of price target drops and downgrades, but...
Read More >> -
UPDATE: Cantor Fitzgerald Initiates Coverage on Sirona Dental Systems
Tuesday, May 22, 2012 - 9:34amAccording to a research report published this morning, Cantor Fitzgerald has initiated Sirona Dental Systems (NASDAQ: SIRO) with a Buy rating and $57. Cantor Fitzgerald commented, "Sirona is global leader in the fast-growing and under-penetrated CAD/CAM services and dental imaging markets, but at...
Read More >> -
UPDATE: Cantor Fitzgerald Initiates Coverage on Align Technology
Tuesday, May 22, 2012 - 9:26amAccording to a research report published this morning, Cantor Fitzgerald has initiated Align Technology (NASDAQ: ALGN) with a Buy rating and $37 PT. In the report, Cantor Fitzgerald said, "With its Invisalign brand of clear aligners, Align has become one of the largest players in the $1.5 billion...
Read More >> -
Friday, May 18, 2012 - 10:32am
Benzinga's Top Downgrades With Color for May 18, 2012
Listed below are today's Top Downgrades at Benzinga: Cantor Fitzgerald Downgrades SatCon Technology (NASDAQ: SATC) to Hold: Cantor Fitzgerald went on to say “This takes the nascent U.S. solar industry evolution out of the hands of entrepreneurs and technologists and into the hands of politicians...
Read More >> -
UPDATE: Cantor Fitzgerald Downgrades Power-One to Hold, Lowers PT
Friday, May 18, 2012 - 10:16amIn a company update published earlier today, Cantor Fitzgerald downgraded its rating for Power-One, Inc. (NASDAQ: PWER) from Buy to Hold, and lowered its price target from $7.50 to $5.00. Cantor Fitzgerald went on to say “On May 17, the U.S. Department of Commerce imposed an immediate 31% duty on...
Read More >> -
UPDATE: Cantor Fitzgerald Downgrades SatCon Technology to Hold
Friday, May 18, 2012 - 9:53amIn a company update published earlier today, Cantor Fitzgerald L.P. downgraded its rating for SatCon Technology Corporation (NASDAQ: SATC) from Buy to Hold, and maintained its price target of $0.50. Cantor Fitzgerald went on to say “This takes the nascent U.S. solar industry evolution out of the...
Read More >> -
UPDATE: Cantor Fitzgerald Raises Digital Realty's PT
Tuesday, May 15, 2012 - 8:41amAccording to a research report published this morning, Cantor Fitzgerald has increased Digital Realty's (NYSE: DLR) PT from $69 to $71.50. In the report, Cantor Fitzgerald said, "We view the current valuation levels as expensive (currently a 22% premium to our NAV). Our $71.50 price target applies...
Read More >>
